|
 
BOAN BIOTECH(6955)
Analysis：
BOAN Biotech is a comprehensive biopharmaceutical company specializing in the research, development, production, and commercialization of biologics, focusing on therapeutic areas such as oncology, autoimmune diseases, ophthalmology, and metabolic disorders. The group conducts drug discovery activities around multiple platforms, including: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, an antibody-drug conjugate (ADC) technology platform, and a cell therapy platform.
The group’s operations span the entire industry chain, covering antibody discovery, cell line development, upstream and downstream process development, analytical and bioanalytical method development, technology transfer, preclinical studies, clinical research, regulatory affairs, registration, and commercial-scale production. In the field of cell therapy, the group focuses on next-generation enhanced and regulated CAR-T technology, developing safer, more effective, and affordable treatment products for patients. The group’s product portfolio includes three commercialized products: Boyounuo, Boyoubei and Boluojia, which have been successfully launched in mainland China and sold to over 2,928 target hospitals and institutions. The group has initiated several post-marketing clinical observational studies for Boyounuo and Boyoubei.
The group has sufficient production capacity to meet commercial demands. As of December 31, 2024, its commercial production capacity was 9,000L, with a pilot-scale capacity of 2,000L. By improving and upgrading production processes for existing products, advancing digital manufacturing, and adopting domestic substitutes to reduce production costs, the group has significantly enhanced quality and efficiency. Its product pipeline includes several innovative biologics with international intellectual property protection and multiple biosimilar candidates. Beyond China, the group is also developing biopharmaceutical products in overseas markets such as the United States, the European Union, and Japan. Two candidate drugs, BA5101 and BA9101, have entered the Biologics License Application (BLA) stage in China. Notably, BA5101 is reportedly the only one biosimilar of Trulicity in the world to have submitted a BLA. The group is actively exploring external business development and out-licensing arrangements. In January 2024, the group entered into an agreement with Joincare Pharmaceutical Group for the exclusive authorization and commercialization of BA2101 in mainland China for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. The group also signed an agreement with Zencore Biologics, granting non-exclusive use of its proprietary BA-HIEXcell stable cell line development platform in mainland China for the development of various antibodies and therapeutic protein drugs. In November 2024, the group entered into a licensing agreement with a strategic partner to commercialize denosumab injections (BA6101 and BA1102) in the Brazilian market. Additionally, it has engaged in discussions with multiple pharmaceutical companies (including multinationals) and investment institutions regarding licensing or co-development of its innovative drug pipeline and is exploring international commercialization opportunities with overseas partners for products already launched or having completed clinical trials in China.(I do not hold the above-mentioned stock.)
Strategy：
Buy-in Price: $18.50, Target Price: $20.50, Cut Loss Price: $17.50
| 
ZHOU HEI YA(1458)
Analysis：
On July 18th, the company released an earnings forecast, projecting total revenue of 1.2-1.24 billion yuan (RMB, the same below) for the first half of 2025 with a year-on-year decrease of 1.5%-4.7%. Profit for the period is expected to be 90-113 million yuan with a year-on-year increase of 55.2%-94.8%. This is primarily due to the company's optimized store structure and focus on improving store operations, which has effectively increased average single-store sales. Furthermore, declining raw material costs have driven an increase in gross profit margin, and coupled with lean management practices that have optimized the sales expense ratio, this has improved the company's overall profitability. The snack food industry faces significant competitive pressure. To boost sales, major companies are opting to enter major supermarkets like Costco and Sam's Club. In March of this year, Zhou Hei Ya's "Classic Marinated Seasoning Pack" ranked among the top ten most popular seasonings and pickles on Sam's Club and the top of JD.com's best-selling list within its first month of release. Recently, Zhou Hei Ya's "Flavored Duck Sauce" has become available exclusively through Sam's Club stores and the Sam's Club app, signaling significant progress in its development of emerging channels and it is expected to contribute to the company's revenue growth.
Strategy：
Buy-in Price: $2.70, Target Price: $3.00, Cut Loss Price: $2.56
|
|
JIANGXI COPPER (358.HK) - The work plan for stabilizing growth in key industries will be released soon, boosting market sentiment
Company ProfileJiangxi Copper is a leading copper producer in China, primarily engaged in copper mining, smelting, processing, and sales. The company boasts abundant copper resource reserves and advanced production technologies. Its products include copper concentrates, copper cathodes, and copper materials, which are widely used in industries such as power, construction, and transportation. Performance HighlightsIn Q1 2025 (According to Chinese accounting standards), the company's revenue was RMB 111.61 billion, down 8.9% year-on-year; net profit attributable to shareholders after deducting non-recurring items was RMB 2.48 billion, up 37.08% year-on-year, mainly due to the fair value changes in financial assets and liabilities and related disposal gains and losses; EPS was RMB 0.57, up 14% year-on-year; net operating cash flow was RMB 558 million, up 109.2% year-on-year, mainly due to the increase in notes payable and accounts payable. In 2024, the company's revenue was RMB 519.25 billion, down 0.21% year-on-year; net profit attributable to shareholders was RMB 6.9 billion, up 2.3% year-on-year; EPS was RMB 2.00, up 2.56% year-on-year; dividend per share was RMB 0.7 in 2024, and the dividend payout ratio has increased for three consecutive years, indicating that the company attaches importance to shareholder returns. Chart 1: Dividend payout ratio
Resources: Annual Report, PSHK Copper and gold production grew steadilyIn 2024, the company's cathode copper production was 2.29 million tonnes with a year-on-year increase of 9.28%, and sales were 2.29 million tonnes with a year-on-year increase of 9.24%; gold production was 118.26 tonnes with a year-on-year increase of 4.99%, and sales were 119.09 tonnes with a year-on-year increase of 5.65%. The company gave guidance on the production and operation plan for 2025: production of 200,000 tonnes of copper concentrate, 2.37 million tonnes of copper cathode, 139 tonnes of gold, 1,243 tonnes of silver, 6.53 million tonnes of sulphuric acid and 2.01 million tonnes of copper processing materials. Chart 2: Analysis for production and sales
Resources: Annual Report, PSHK The Aynak copper mine project has been restarted, and the company's production capacity is expected to be further expandedThe Mes Aynak copper mine project in Afghanistan, in which the company participated, is a key part of China's overseas resource layout. However, due to factors such as safety and cultural protection, the project has gone through 16 years of twists and turns and was finally restarted in July 2024. The company holds a 25% stake in the project, with MCC Group as the lead party and both parties jointly operating. The Mes Aynak copper mine is the world's second largest undeveloped copper mine, with proven resources of 662 million tonnes, copper metal resources of approximately 11.08 million tonnes, and an average grade of 1.67%. After reaching full production, it is expected to produce 220,000 tonnes of refined copper annually, which is expected to further expand the company's production capacity and alleviate China's copper resource consumption gap. Becoming the largest single shareholder of SolGoldIn March 2025, Jiangxi Copper (Hong Kong) Investment Co., Ltd., a wholly-owned subsidiary of the Company, signed a share purchase agreement with SolGold Canada Inc. ("SolGold Canada"), whereby Jiangxi Copper Hong Kong Investment purchased 157 million shares (approximately 5.24% of its issued shares) of SolGold Plc (SolGold), a listed company in London and Toronto, held by SolGold Canada, for a total transaction price of US$18.07 million. Prior to this transaction, Jiangxi Copper Hong Kong Investment already held 209 million shares of SolGold. After the completion of this transaction, Jiangxi Copper Hong Kong Investment will hold a total of 366 million shares of SolGold (approximately 12.19% of its issued shares). After this transaction, Jiangxi Copper will become the largest single shareholder of SolGold. SolGold is a mineral exploration and development company headquartered in Perth, Australia. The core asset is 100% equity of the Cascabel project in Ecuador. The Alpala mineral deposit, the main project, currently has the following proven, controlled and inferred resources: 12.2 million tonnes of copper, 30.5 million ounces of gold, and 102.3 million ounces of silver, of which the proven and probable reserves are: 3.2 million tonnes of copper, 9.4 million ounces of gold, and 28 million ounces of silver. The project has completed a pre-feasibility study. Sol Gold also has dozens of exploration projects at different stages in Ecuador and other places. Jiangxi Copper said that this transaction is in line with the company's development strategy, which will help enhance the company's industry status and help the two companies complement each other's strengths, develop synergistically and enhance their value. Successful deployment in KazakhstanThe Bakuta Tungsten Mine Project is one of the key projects in the capacity cooperation framework between China and Kazakhstan. The project is jointly funded by Jiangxi Copper Group Co., Ltd., Hengzhao International (Hong Kong) Co., Ltd., and China Railway Construction Corporation Limited. The project company in Kazakhstan is Jetsu Tungsten Industry Co., Ltd. The Bakuta Tungsten Mine has a tungsten ore reserve of about 120 million tonnes. It is designed to adopt open-pit mining with an annual mining scale of 3.3 million tonnes. Two years after it is put into production, the mining scale will be increased to 4.95 million tonnes per year through the use of waste disposal technology. The first phase of the Bakuta Tungsten Mine project is expected to achieve commercial production in Q3 2025, and the second phase of the expansion plan is expected to start in Q1 2027, indicating that the company has successfully laid out in Kazakhstan and has taken a further step in its international layout. Investment ThesisThe International Copper Study Group (ICSG) released its monthly report on June 24th, showing that global copper mine production increased by approximately 2% year-over-year to 7.53 million tonnes in the first four months of 2025, with concentrate production increasing by 2.2%. Global refined copper production increased by approximately 3.2% year-over-year to 9.42 million tonnes, and global apparent refined copper demand increased by approximately 3.3% year-over-year to 9.18 million tonnes, with supply slightly exceeding demand. The ICSG's Global Copper Mine and Refined Copper Market Outlook (2025–2026) report indicates that global refined copper production is projected to grow by 2.9% in 2025 and 1.5% in 2026. Global refined copper consumption is projected to grow by 2.4% in 2025, reaching 28 million tonnes. Global refined copper consumption is projected to reach 28.52 million tonnes in 2026. The global refined copper market is projected to have a surplus of 289,000 tonnes in 2025 and 209,000 tonnes in 2026. We believe that while the refined copper market may experience an oversupply by 2025, demand remains strong. New energy vehicles and home appliance consumption, benefiting from the trade-in policy, will become key growth drivers for global copper consumption. Due to the recent impact of the Sino-US trade war, China has reduced its imports of scrap copper from the United States, which is expected to further increase China's refined copper consumption. The Ministry of Industry and Information Technology recently held a press conference, announcing the implementation of a new round of work plans to stabilize growth in ten key industries, including steel, nonferrous metals, and petrochemicals. This plan aims to promote structural adjustments, optimize supply, and eliminate outdated production capacity in key sectors, boosting market sentiment and potentially supporting copper prices in the short term. Chart 3: Price of LME Copper
Resources: WIND, PSHK We forecast the company's operating revenue to reach 516.65 billion yuan, 542.48 billion yuan, and 558.76 billion yuan in 2025-2027 respectively. BVPS are 23.8, 25.1, and 26.5 yuan, corresponding to P/B of 0.65x, 0.61x, and 0.58x. We believe the company has medium-term growth potential and assign a target price of HK$18.22 in 2025, corresponding to a P/B of 0.7x. We maintain the “Accumulate" rating. (Current price as of July 29) Risk Factors1) Changes in the macroeconomic environment;
2) Market environment changes;
3) Product price fluctuations;
4) Impact of safety incidents;
5) Exchange rate fluctuations;
6) Product substitution risks;
7) Environmental risks. Financials
Current Price as of: 29 Jul
Source: PSHK Est. Download PDF version...
| Recommendation on 30-7-2025 | | Recommendation | Accumulate | | Price on Recommendation Date | $ 16.800 | | Suggested purchase price | N/A | | Target Price | $ 18.220 |
| |
|
|
|
|
| Stock Code |
H share
Price |
A share
Price |
H share
discount |
| | | |
|
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.
If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.
版權所有， 翻印必究。
Copyright(C) 2025 Phillip Securities (HK) Ltd. All Rights Reserved.
|
